NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

hey Maverick, this “concern” is often regurgitated by the naysayers. As exwannabe has said countless times, Northwest Bio is not alone, and there have been numerous companies running clinical trials with dendritic cells, many of which have failed. However, there are a number of different ways to produce and activate dendritic cells, and what Dr. Liau is saying is that the specific process that Northwest Bio has optimized and perfected, (i.e. the exact media mix, length of time to mature them, etc.) is considered an “art” and that process is what is patented. In the last part, I think she believes that a company can attempt to patent a specific target like the expression of CD19 on B cell non-Hodgkin lymphoma which has been identified as a target for CAR T-Cell therapies, but this would certainly not work for Glioblastoma which has a high degree of mutation. This is exactly why DCVax, which is personalized to each individual patient's own tumor and uses ALL of that patient’s antigens (potential mutation pathways) to prevent the cancer from evading it, is the most effective treatment for Glioblastoma to date. Additionally, what she doesn’t say in that interview, (which I think was a year ago???) is that the trial itself and orphan status, will insure that Northwest Bio will own the market for Glioblastoma for nearly a decade, even if any real competition comes along.